Duchesnay USA Supports the Food and Drug Administration's (FDA) Decision to Revise System Explaining the Risks of Medicines During Pregnancy

News provided by

Dec 09, 2014, 12:51 ET

ROSEMONT, Pa., Dec. 9, 2014 /PRNewswire/ -- Following more than six years of debate and a panel discussion held in May 2014, the FDA has decided to change how drug companies are required to present the risks of taking medicine during pregnancy and while breastfeeding. The new system replaces a system that officials described as confusing and outdated with a clearer, more consistent explanation of risks.

As a research-based company dedicated to the well-being and health of pregnant women and their unborn children, Duchesnay USA applauds the FDA in the agency's decision to revise the current system. Considering there are more than six million pregnancies in the United States every year and that women typically take three to five prescription drugs during the course of their pregnancies, this is an important change that has the potential to clarify a concern that has long caused significant anxiety for pregnant women. This is an important first step in ensuring that appropriate information is researched and shared concerning medication use in pregnancy.

Duchesnay USA supports the FDA as it continues efforts to safeguard the health of pregnant women and their unborn children. We have always been committed to providing pregnant women with safe and effective pharmacological treatments, and we will continue to provide evidence-based information that enables healthcare professionals to make informed decisions when prescribing medication for their patients.

About Duchesnay USA
Duchesnay USA is a unique healthcare company devoted to safeguarding the health and well-being of expectant mothers and their unborn babies. Its affiliate company, Duchesnay Inc., was founded in 1970 in Canada. The family-owned company realigned its business in 1992 to focus specifically on pregnant women after a family member experienced a very difficult pregnancy. Duchesnay's mission is to develop pharmacological solutions to reduce the symptoms of nausea and vomiting during pregnancy (NVP). Duchesnay USA was established in Rosemont, Pennsylvania in 2011 to pursue that same mission. Realizing a lack of sufficient information on medications for use in pregnancy, Duchesnay strives today to ensure that expectant women who require pharmacological treatments have access to proper medical advice and therapies that are safe for them and their unborn babies. For more information on Duchesnay USA, please visit www.DuchesnayUSA.com.

Contact
Laney Cohen
Makovsky
[email protected]
212-508-9643

Logo - http://photos.prnewswire.com/prnh/20130521/NY17121LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/duchesnay-usa-supports-the-food-and-drug-administrations-fda-decision-to-revise-system-explaining-the-risks-of-medicines-during-pregnancy-300007048.html

SOURCE Duchesnay USA